CN102574782B - 取代的卤代苯氧基苯甲酰胺衍生物 - Google Patents

取代的卤代苯氧基苯甲酰胺衍生物 Download PDF

Info

Publication number
CN102574782B
CN102574782B CN201080047110.3A CN201080047110A CN102574782B CN 102574782 B CN102574782 B CN 102574782B CN 201080047110 A CN201080047110 A CN 201080047110A CN 102574782 B CN102574782 B CN 102574782B
Authority
CN
China
Prior art keywords
compound
acid
general formula
salt
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080047110.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102574782A (zh
Inventor
M·希契科克
I·哈通
F·普勒
G·西迈斯特
R·诺伊豪斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Intellectual Property GmbH filed Critical Bayer Pharma AG
Publication of CN102574782A publication Critical patent/CN102574782A/zh
Application granted granted Critical
Publication of CN102574782B publication Critical patent/CN102574782B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201080047110.3A 2009-10-21 2010-10-12 取代的卤代苯氧基苯甲酰胺衍生物 Expired - Fee Related CN102574782B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075470 2009-10-21
EP09075470.6 2009-10-21
PCT/EP2010/006235 WO2011047796A1 (en) 2009-10-21 2010-10-12 Substituted halophenoxybenzamide derivatives

Publications (2)

Publication Number Publication Date
CN102574782A CN102574782A (zh) 2012-07-11
CN102574782B true CN102574782B (zh) 2014-10-08

Family

ID=43086963

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080047110.3A Expired - Fee Related CN102574782B (zh) 2009-10-21 2010-10-12 取代的卤代苯氧基苯甲酰胺衍生物

Country Status (6)

Country Link
US (1) US20120263714A1 (https=)
EP (1) EP2491014A1 (https=)
JP (1) JP2013508320A (https=)
CN (1) CN102574782B (https=)
CA (1) CA2777071A1 (https=)
WO (1) WO2011047796A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115803024B (zh) * 2020-07-22 2025-01-10 中外制药株式会社 包含芳基酰胺衍生物的组合物
CN116930478A (zh) * 2022-04-02 2023-10-24 迈克生物股份有限公司 一种甲状腺素荧光偶联物及其制备方法和应用
CN121511080A (zh) * 2023-07-06 2026-02-10 华健未来（成都）科技股份有限公司 一类芳香酰胺类衍生物及其用途
WO2025146040A1 (zh) * 2024-01-01 2025-07-10 华健未来（成都）科技股份有限公司 芳香酰肼类衍生物及其医药用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083167A1 (ja) * 2003-03-18 2004-09-30 Sankyo Company Limited スルファミド誘導体及びその医薬組成物
CN1681557A (zh) * 2002-08-07 2005-10-12 法玛西雅公司 治疗碳酸酐酶介导的疾病的方法
CN1906183A (zh) * 2003-11-13 2007-01-31 艾博特公司 N－酰基磺酰胺细胞程序死亡促进剂
CN101006072A (zh) * 2004-06-16 2007-07-25 詹森药业有限公司 用于治疗癫痫和相关疾病的氨基磺酸酯和氨基磺酰胺衍生物
CN101282948A (zh) * 2005-10-07 2008-10-08 埃克塞里艾克西斯公司 N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途
TW200911224A (en) * 2007-05-11 2009-03-16 Bayer Schering Pharma Ag Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
ATE320796T1 (de) 1996-12-23 2006-04-15 Sla Pharma Ag Pharmazeutische zubereitung zur behandlung der analinkontinenz und analem juckreiz
WO1998037881A1 (en) 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
CA2290509A1 (en) 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
AU2180500A (en) 1998-12-15 2000-07-03 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
AU776788C (en) 1998-12-16 2005-10-27 Warner-Lambert Company Treatment of arthritis with MEK inhibitors
AU2203800A (en) 1999-01-07 2000-07-24 Warner-Lambert Company Antiviral method using mek inhibitors
JP2002534380A (ja) 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による喘息の治療
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
HUP0105092A3 (en) 1999-01-13 2003-12-29 Warner Lambert Co 1-heterocycle substituted diarylamines and medicaments containing them
CA2355470C (en) 1999-01-13 2008-09-30 Warner-Lambert Company Benzoheterocycles and their use as mek inhibitors
EP1144372B1 (en) 1999-01-13 2005-11-30 Warner-Lambert Company Llc Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
EP1150950A2 (en) 1999-01-13 2001-11-07 Warner-Lambert Company Anthranilic acid derivatives
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
EP1202732A2 (en) 1999-07-16 2002-05-08 Warner-Lambert Company Llc Method for treating chronic pain using mek inhibitors
CA2377092A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
JP2003504401A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法
JP2003504400A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いた慢性痛の治療方法
BR0109188A (pt) 2000-03-15 2003-03-18 Warner Lambert Co Diarilaminas 5-amida substituìdas como inibidores de mex
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
WO2003013655A2 (en) * 2001-08-10 2003-02-20 Pharmacia Corporation Carbonic anhydrase inhibitors
EP1438295B1 (en) 2001-10-23 2012-08-15 Merck Serono SA Azole derivatives and pharmaceutical compositions containing them
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
EP1467968A1 (en) 2002-01-23 2004-10-20 Warner-Lambert Company LLC N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
WO2005007616A1 (en) 2003-07-23 2005-01-27 Warner-Lambert Company Llc Diphenylamino ketone derivatives as mek inhibitors
CA2532067C (en) 2003-07-24 2010-12-21 Stephen Douglas Barrett N-methyle-substituted benzamidazoles
DE10341477A1 (de) 2003-09-05 2005-03-31 Riehle, Rainer, Dipl.-Ing. Schallgenerator zur Erzeugung in Rohrleitungen eines Wasser- oder Gasversorgungssystems ausbreitungsfähiger Schallimpulse
US8084645B2 (en) 2003-09-19 2011-12-27 Chugai Seiyaku Kabushiki Kaisha 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
CA2546353A1 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
AU2005252110B2 (en) 2004-06-11 2008-09-04 Shionogi & Co., Ltd. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer
TW200621766A (en) 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
EP1794134A1 (de) * 2004-09-29 2007-06-13 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel
WO2006056427A1 (en) 2004-11-24 2006-06-01 Laboratoires Serono S.A. Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders
WO2006114466A1 (es) 2005-04-28 2006-11-02 Uson Calvo Aurelio Batea urológica polivalente
WO2008124703A2 (en) * 2007-04-05 2008-10-16 Siemens Medical Solutions Usa, Inc. Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry
AR070949A1 (es) * 2007-10-19 2010-05-19 Solvay Pharm Gmbh Compuestos derivados de sulfamato de uso medico, medicamentos y composiciones farmaceuticas que los comprenden, procedimientos para preparar estos compuestos y su uso
US20110039819A1 (en) * 2008-04-22 2011-02-17 Marion Hitchcock Substituted phenoxybenzamides
WO2010051935A2 (en) * 2008-11-10 2010-05-14 Bayer Schering Pharma Aktiengesellschaft Substituted amido phenoxybenzamides
EP2491015A1 (en) * 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1681557A (zh) * 2002-08-07 2005-10-12 法玛西雅公司 治疗碳酸酐酶介导的疾病的方法
WO2004083167A1 (ja) * 2003-03-18 2004-09-30 Sankyo Company Limited スルファミド誘導体及びその医薬組成物
CN1906183A (zh) * 2003-11-13 2007-01-31 艾博特公司 N－酰基磺酰胺细胞程序死亡促进剂
CN101006072A (zh) * 2004-06-16 2007-07-25 詹森药业有限公司 用于治疗癫痫和相关疾病的氨基磺酸酯和氨基磺酰胺衍生物
CN101282948A (zh) * 2005-10-07 2008-10-08 埃克塞里艾克西斯公司 N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途
TW200911224A (en) * 2007-05-11 2009-03-16 Bayer Schering Pharma Ag Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity

Also Published As

Publication number Publication date
EP2491014A1 (en) 2012-08-29
HK1173134A1 (en) 2013-05-10
JP2013508320A (ja) 2013-03-07
WO2011047796A1 (en) 2011-04-28
CN102574782A (zh) 2012-07-11
US20120263714A1 (en) 2012-10-18
CA2777071A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
CN102753547B (zh) 三唑并吡啶衍生物
CN102762557B (zh) 三唑并吡啶
JP5728683B2 (ja) チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
CN102413831B (zh) 取代的咪唑并喹喔啉
JP6174586B2 (ja) 置換イミダゾピリダジン
JP5667044B2 (ja) 置換されたフェノキシベンズアミド
US20140187548A1 (en) 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103582632B (zh) 取代的苯并咪唑
WO2008138639A1 (en) Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity
JP5732662B2 (ja) 置換アミドフェノキシベンズアミド
CN102574782B (zh) 取代的卤代苯氧基苯甲酰胺衍生物
CN103282351A (zh) 取代的苯氧基吡啶
CN102656142A (zh) 取代的苯磺酰胺
HK1173134B (en) Substituted halophenoxybenzamide derivatives
HK1188999A (en) Substituted phenoxypyridines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1173134

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

Free format text: FORMER OWNER: BAYER PHARMA AG

Effective date: 20130723

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130723

Address after: German Monheim

Applicant after: Bayer Pharma Aktiengesellschaft

Address before: Berlin

Applicant before: Bayer Pharma AG

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1173134

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141008

Termination date: 20161012

CF01 Termination of patent right due to non-payment of annual fee